Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), is expanding the universe of druggable targets by enabling the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells. The team is committed to leveraging ARMMs technology to develop transformative medicines and address currently unmet medical needs.

Biotechnology

Vesigen Therapeutics

Paulash Mohsen

Qin Yu

Yashodhan Chinchore

Thomas Bordner

Steve Greenway

Shu-Lin Liu

Kristin Luther

Lorien Moore

Qiyu W.

Gang (Gary) Hao

Joseph Nabhan

The board of directors at Vesigen Therapeutics has a history of experience with research and development in the medical field. They have worked as scientists at various renowned institutes, such as the Broad Institute of MIT and Harvard, and have conducted research in various areas related to neurobiology and stem cells. They also hold degrees from top universities, such as Nanjing University and UT Health San Antonio.

Board of Directors

CEO and Executive Team

Leadership Team

Board of Directors

About

Team members

Other teams at Vesigen Therapeutics

CEO and Executive Team

Leadership Team